233 related articles for article (PubMed ID: 34200318)
1. Targeting Tissue Factor to Tumor Vasculature to Induce Tumor Infarction.
Berdel AF; Schwöppe C; Brand C; Harrach S; Brömmel K; Hintelmann H; Lenz G; Liersch R; Heinzow H; Schliemann C; Mesters RM; Berdel WE; Kessler T
Cancers (Basel); 2021 Jun; 13(11):. PubMed ID: 34200318
[TBL] [Abstract][Full Text] [Related]
2. NG2 proteoglycan as a pericyte target for anticancer therapy by tumor vessel infarction with retargeted tissue factor.
Brand C; Schliemann C; Ring J; Kessler T; Bäumer S; Angenendt L; Mantke V; Ross R; Hintelmann H; Spieker T; Wardelmann E; Mesters RM; Berdel WE; Schwöppe C
Oncotarget; 2016 Feb; 7(6):6774-89. PubMed ID: 26735180
[TBL] [Abstract][Full Text] [Related]
3. Non-invasive monitoring of tumor-vessel infarction by retargeted truncated tissue factor tTF-NGR using multi-modal imaging.
Persigehl T; Ring J; Bremer C; Heindel W; Holtmeier R; Stypmann J; Claesener M; Hermann S; Schäfers M; Zerbst C; Schliemann C; Mesters RM; Berdel WE; Schwöppe C
Angiogenesis; 2014 Jan; 17(1):235-46. PubMed ID: 24136410
[TBL] [Abstract][Full Text] [Related]
4. Combinatorial effects of doxorubicin and retargeted tissue factor by intratumoral entrapment of doxorubicin and proapoptotic increase of tumor vascular infarction.
Stucke-Ring J; Ronnacker J; Brand C; Höltke C; Schliemann C; Kessler T; Schmidt LH; Harrach S; Mantke V; Hintelmann H; Hartmann W; Wardelmann E; Lenz G; Wünsch B; Müller-Tidow C; Mesters RM; Schwöppe C; Berdel WE
Oncotarget; 2016 Dec; 7(50):82458-82472. PubMed ID: 27738341
[TBL] [Abstract][Full Text] [Related]
5. Tumor Growth Inhibition via Occlusion of Tumor Vasculature Induced by N-Terminally PEGylated Retargeted Tissue Factor tTF-NGR.
Brand C; Fröhlich M; Ring J; Schliemann C; Kessler T; Mantke V; König S; Lücke M; Mesters RM; Berdel WE; Schwöppe C
Mol Pharm; 2015 Oct; 12(10):3749-58. PubMed ID: 26310827
[TBL] [Abstract][Full Text] [Related]
6. Radiation synergizes with antitumor activity of CD13-targeted tissue factor in a HT1080 xenograft model of human soft tissue sarcoma.
Brand C; Greve B; Bölling T; Eich HT; Willich N; Harrach S; Hintelmann H; Lenz G; Mesters RM; Kessler T; Schliemann C; Berdel WE; Schwöppe C
PLoS One; 2020; 15(2):e0229271. PubMed ID: 32084238
[TBL] [Abstract][Full Text] [Related]
7. First-In-Class CD13-Targeted Tissue Factor tTF-NGR in Patients with Recurrent or Refractory Malignant Tumors: Results of a Phase I Dose-Escalation Study.
Schliemann C; Gerwing M; Heinzow H; Harrach S; Schwöppe C; Wildgruber M; Hansmeier AA; Angenendt L; Berdel AF; Stalmann U; Berning B; Kratz-Albers K; Middelberg-Bisping K; Wiebe S; Albring J; Wilms C; Hartmann W; Wardelmann E; Krähling T; Heindel W; Gerss J; Bormann E; Schmidt H; Lenz G; Kessler T; Mesters RM; Berdel WE
Cancers (Basel); 2020 Jun; 12(6):. PubMed ID: 32517329
[TBL] [Abstract][Full Text] [Related]
8. Low-Energy Ultrasound Treatment Improves Regional Tumor Vessel Infarction by Retargeted Tissue Factor.
Brand C; Dencks S; Schmitz G; Mühlmeister M; Stypmann J; Ross R; Hintelmann H; Schliemann C; Müller-Tidow C; Mesters RM; Berdel WE; Schwöppe C
J Ultrasound Med; 2015 Jul; 34(7):1227-36. PubMed ID: 26112625
[TBL] [Abstract][Full Text] [Related]
9. Gadofosveset-enhanced MRI as simple surrogate parameter for real-time evaluation of the initial tumour vessel infarction by retargeted tissue factor tTF-NGR.
Höink A; Persigehl T; Kwiecien R; Balthasar M; Mesters R; Berdel W; Heindel W; Bremer C; Schwöppe C
Oncol Lett; 2019 Jan; 17(1):270-280. PubMed ID: 30655764
[TBL] [Abstract][Full Text] [Related]
10. Infarction of tumor vessels by NGR-peptide-directed targeting of tissue factor: experimental results and first-in-man experience.
Bieker R; Kessler T; Schwöppe C; Padró T; Persigehl T; Bremer C; Dreischalück J; Kolkmeyer A; Heindel W; Mesters RM; Berdel WE
Blood; 2009 May; 113(20):5019-27. PubMed ID: 19179306
[TBL] [Abstract][Full Text] [Related]
11. Vascular infarction by subcutaneous application of tissue factor targeted to tumor vessels with NGR-peptides: activity and toxicity profile.
Dreischalück J; Schwöppe C; Spieker T; Kessler T; Tiemann K; Liersch R; Schliemann C; Kreuter M; Kolkmeyer A; Hintelmann H; Mesters RM; Berdel WE
Int J Oncol; 2010 Dec; 37(6):1389-97. PubMed ID: 21042706
[TBL] [Abstract][Full Text] [Related]
12. CD13 as target for tissue factor induced tumor vascular infarction in small cell lung cancer.
Schmidt LH; Stucke-Ring J; Brand C; Schliemann C; Harrach S; Muley T; Herpel E; Kessler T; Mohr M; Görlich D; Kreuter M; Lenz G; Wardelmann E; Thomas M; Berdel WE; Schwöppe C; Hartmann W
Lung Cancer; 2017 Nov; 113():121-127. PubMed ID: 29110838
[TBL] [Abstract][Full Text] [Related]
13. Generation of fusion proteins for selective occlusion of tumor vessels.
Kessler T; Schwöppe C; Liersch R; Schliemann C; Hintelmann H; Bieker R; Berdel WE; Mesters RM
Curr Drug Discov Technol; 2008 Mar; 5(1):1-8. PubMed ID: 18537561
[TBL] [Abstract][Full Text] [Related]
14. Potential therapeutic impact of CD13 expression in non-small cell lung cancer.
Schmidt LH; Brand C; Stucke-Ring J; Schliemann C; Kessler T; Harrach S; Mohr M; Görlich D; Marra A; Hillejan L; Müller-Tidow C; Lenz G; Wardelmann E; Wiewrodt R; Berdel WE; Schwöppe C; Hartmann W
PLoS One; 2017; 12(6):e0177146. PubMed ID: 28604784
[TBL] [Abstract][Full Text] [Related]
15. Tissue-factor fusion proteins induce occlusion of tumor vessels.
Schwöppe C; Kessler T; Persigehl T; Liersch R; Hintelmann H; Dreischalück J; Ring J; Bremer C; Heindel W; Mesters RM; Berdel WE
Thromb Res; 2010 Apr; 125 Suppl 2():S143-50. PubMed ID: 20433995
[TBL] [Abstract][Full Text] [Related]
16. Aminopeptidase N (CD13): Expression, Prognostic Impact, and Use as Therapeutic Target for Tissue Factor Induced Tumor Vascular Infarction in Soft Tissue Sarcoma.
Kessler T; Baumeier A; Brand C; Grau M; Angenendt L; Harrach S; Stalmann U; Schmidt LH; Gosheger G; Hardes J; Andreou D; Dreischalück J; Lenz G; Wardelmann E; Mesters RM; Schwöppe C; Berdel WE; Hartmann W; Schliemann C
Transl Oncol; 2018 Dec; 11(6):1271-1282. PubMed ID: 30125801
[TBL] [Abstract][Full Text] [Related]
17. Tumor vascular infarction: prospects and challenges.
Jahanban-Esfahlan R; Seidi K; Zarghami N
Int J Hematol; 2017 Mar; 105(3):244-256. PubMed ID: 28044258
[TBL] [Abstract][Full Text] [Related]
18. pHLIP-mediated targeting of truncated tissue factor to tumor vessels causes vascular occlusion and impairs tumor growth.
Li S; Tian Y; Zhao Y; Zhang Y; Su S; Wang J; Wu M; Shi Q; Anderson GJ; Thomsen J; Zhao R; Ji T; Wang J; Nie G
Oncotarget; 2015 Sep; 6(27):23523-32. PubMed ID: 26143637
[TBL] [Abstract][Full Text] [Related]
19. Molecularly engineered truncated tissue factor with therapeutic aptamers for tumor-targeted delivery and vascular infarction.
Li B; Wei J; Di C; Lu Z; Qi F; Zhang Y; Leong WS; Li L; Nie G; Li S
Acta Pharm Sin B; 2021 Jul; 11(7):2059-2069. PubMed ID: 34386338
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of tumor growth by RGD peptide-directed delivery of truncated tissue factor to the tumor vasculature.
Kessler T; Bieker R; Padró T; Schwöppe C; Persigehl T; Bremer C; Kreuter M; Berdel WE; Mesters RM
Clin Cancer Res; 2005 Sep; 11(17):6317-24. PubMed ID: 16144936
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]